192 related articles for article (PubMed ID: 38116291)
21. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
[TBL] [Abstract][Full Text] [Related]
22. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
[No Abstract] [Full Text] [Related]
23. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
24. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
25. Current status and future perspectives of liquid biopsy in non-small cell lung cancer.
Chang S; Hur JY; Choi YL; Lee CH; Kim WS
J Pathol Transl Med; 2020 May; 54(3):204-212. PubMed ID: 32460474
[TBL] [Abstract][Full Text] [Related]
26. Comparison of two next-generation sequencing-based approaches for liquid biopsy analysis in patients with non-small cell lung cancer: a multicentre study.
Bessi S; Pepe F; Russo G; Pisapia P; Ottaviantonio M; Biancalani F; Iaccarino A; Russo M; Biancalani M; Troncone G; Malapelle U
J Clin Pathol; 2023 Mar; 76(3):206-210. PubMed ID: 35701144
[TBL] [Abstract][Full Text] [Related]
27. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
28. Validation of Cell-Free DNA Collection Tubes for Determination of EGFR Mutation Status in Liquid Biopsy from NSCLC Patients.
Sesé M; Somoza R; Maestu I; Ureste MM; Sanchez A; Cordoba JF; Sansano I; Venturas G; Ramón Y Cajal S; Hernández-Losa J
Oncol Ther; 2019 Dec; 7(2):131-139. PubMed ID: 32699985
[TBL] [Abstract][Full Text] [Related]
29. Concordance analysis between liquid biopsy (ctDNA) and tumor DNA molecular profiles from panel-based next-generation sequencing.
Rodon Font N; No Garbarino Y; Díaz Castello O; Moya Amoros J; Barrios Sánchez P; Coroleu Lletget D; Lequerica Cabello MA; Borras Marcet J; Mecho Meca S; Escape I; Martinez-Agea J; Garcia E; Ferrer M; Puig Torrus X
Rev Esp Patol; 2022; 55(3):156-162. PubMed ID: 35779881
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
31. Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience.
Ulivi P; Petracci E; Canale M; Priano I; Capelli L; Calistri D; Chiadini E; Cravero P; Rossi A; Delmonte A; Crinò L; Bronte G
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680416
[TBL] [Abstract][Full Text] [Related]
32. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
[TBL] [Abstract][Full Text] [Related]
33. Applications of Liquid Biopsies in Non-Small-Cell Lung Cancer.
Pesta M; Shetti D; Kulda V; Knizkova T; Houfkova K; Bagheri MS; Svaton M; Polivka J
Diagnostics (Basel); 2022 Jul; 12(8):. PubMed ID: 35892510
[TBL] [Abstract][Full Text] [Related]
34. Re-biopsy and liquid biopsy for patients with non-small cell lung cancer after EGFR-tyrosine kinase inhibitor failure.
Zhou J; Zhao C; Zhao J; Wang Q; Chu X; Li J; Zhou F; Ren S; Li X; Su C; Zhou C
Thorac Cancer; 2019 Apr; 10(4):957-965. PubMed ID: 30887673
[TBL] [Abstract][Full Text] [Related]
35. Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Fu Y; Wang A; Zhou J; Feng W; Shi M; Xu X; Zhao H; Cai L; Feng J; Lv X; Zhang X; Xu W; Zhang Z; Ma G; Wang J; Zhou T; Zhao D; Fang H; Liu Z; Huang JA
Front Oncol; 2021; 11():621992. PubMed ID: 33718183
[TBL] [Abstract][Full Text] [Related]
36. Up-front mutation detection in circulating tumor DNA by droplet digital PCR has added diagnostic value in lung cancer.
Visser E; de Kock R; Genet S; Borne BVD; Soud MY; Belderbos H; Stege G; de Saegher M; 't Westeinde SV; Broeren M; Eduati F; Deiman B; Scharnhorst V
Transl Oncol; 2023 Jan; 27():101589. PubMed ID: 36413862
[TBL] [Abstract][Full Text] [Related]
37. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer.
Nagasaka M; Uddin MH; Al-Hallak MN; Rahman S; Balasubramanian S; Sukari A; Azmi AS
Mol Cancer; 2021 Jun; 20(1):82. PubMed ID: 34074295
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of different platforms in detecting EGFR mutations using cerebrospinal fluid cell-free DNA from non-small-cell lung cancer patients with leptomeningeal metastases.
Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
Thorac Cancer; 2023 May; 14(14):1251-1259. PubMed ID: 36977550
[TBL] [Abstract][Full Text] [Related]
39. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
[TBL] [Abstract][Full Text] [Related]
40. Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients.
Zulato E; Tosello V; Nardo G; Bonanno L; Del Bianco P; Indraccolo S
Diagnostics (Basel); 2021 Aug; 11(8):. PubMed ID: 34441402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
